Small Cap Feast

6th February 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings:




Whats baking in the oven?

Potential Initial Public Offerings:

12 January: The London Tunnels PLC announces its intention to seek Admission to the Standard Segment of the Official List and to trading on the Main Market of the LSE. The Company plans to restore, adaptively reuse and bring back to life the Kingsway Exchange Tunnels in Central London, originally built in the early 1940’s, and designed to shelter people during the London Blitz. The Company has successfully raised approximately £10m from investors and aims to admit its Ordinary Shares at a price of £2.00 per share to the Main Market. The Company is expected to have a market capitalisation of approximately £123m on Admission. Delayed: Expected Admission was before the end of January 2024.


Reverse Takeovers:

30 January: Location Sciences Group Plc is proposing to acquire the entire issued share capital of Sorted Holdings Limited (Sorted) for a nominal consideration of £1.00 (Acquisition). Sorted operates a software-as-a-service (SaaS) business model providing delivery experience software which serves ecommerce retailers - from large, global enterprises to smaller, independent start-ups. Pursuant to Rule 14 of the AIM Rules for Companies, the Acquisition constitutes a reverse takeover. Capital to be raised on Admission is approximately £2.0m via a subscription for new Ordinary Shares. Anticipated market capitalisation on Admission is approximately £6.68m. Expected AIM Admission date is 19 February 2024.


Change of Market:


Banquet Buffet

Alumasc Group 179p £64.7m (ALU.L)
The sustainable building products, systems and solutions Group announces results for the six months ended 31 December 2023. Group revenues up by 6.4% to £47.8m (H1 FY23: £45.0m), as a result underlying profit before tax grew 12.4% to £6.3m (H1 FY23: £5.6m). Net bank debt at December 2023 was £7.4m (H1 FY2023: £6.8m), after net cash outflow on ARP acquisition of £6.5m which was for a maximum cash consideration of £10.0m on a cash and debt free basis completed in December 2023. The Group's focus on sustainable building products, cost base management and outstanding customer service, will help mitigate the external geopolitical and economic environment, expected to continue to create uncertainty for the remainder of the year.

Biome Technologies 110p £4.2m (BIOM.L)
A bioplastics and radio frequency technology business, provides an unaudited pre-close Trading Update for the financial year ended 31 December 2023. Group revenues for the year ended 31 December 2023 were in line with current market expectations at £7.0m and 13% ahead of the previous year (2022: £6.2m). The Group had a cash balance at the year-end of £0.6m (31 December 2022: £0.8m) and had 2026 convertible loan notes outstanding of £0.85m and no bank debt. The Bioplastics Division revenues for the year to 31 December 2023 were £6.0m, an increase of 36% on the prior year (2022: £4.4m). The Board is pleased with the strong progress of the Bioplastics division throughout 2023.

Eckoh 44p £127.8m (ECK.L)
The provider of Customer Engagement Data Security Solutions, announces an update on total contracted business and new contracted business achieved in H2 FY24 by the end of January. In the first half ended 30 September 2023, Eckoh contracted new business totalling £24.6m. The Group further reports that the strong levels of contract wins has continued in H2 with over £20m of additional contracted business closed since 1 October 2023 and have already exceeded order intakes for a single year with record total contracted business of £45m year-to-date, of which c.£18m is new business. The new UK wins include a 3-year contract with a large UK-based media & telecommunications provider for voice and chat security worth £2.3m.

Filtronic 28.2p £60.7m (FTC.L)
The designer and manufacturer of products for the aerospace, defence, space and telecoms infrastructure markets, announces two significant contract wins with a global provider of low earth orbit (LEO) satellite communications equipment. The production order contract, valued at $9.9m (£7.8m), with revenue expected to be recognised within calendar year 2024, is for additional demand of Filtronic's innovative Cerus32 solid state power amplifier (SSPA) module. The second contract with the same customer is a development agreement to accelerate the design and prototype delivery of an E-band module that would form part of the satellite payload and provide downlink connectivity to the E-band ground station.

Novacyt 49.2p £34.3m (NCYT.L)
An international molecular diagnostics company with a broad portfolio of integrated technologies and services, has received formal notification from INEX Innovate Pte Ltd of its decision to terminate discussions regarding the acquisition of Yourgene Health Taiwan Co Ltd, as originally announced by Yourgene Health plc (Yourgene) on 13 June 2023. As a result, Yourgene's Taiwanese laboratory business will remain part of the Novacyt Group. The Board does not consider the divestment material and will continue to evaluate a number of options in relation to the future of the Taiwanese laboratory business that offer the best value to all stakeholders.

Oracle Power 0.028p £1.3m (ORCP.L)
The international project developer, announce the completion of a technical and commercial feasibility study (Study) undertaken by leading international construction engineering company, China Electric Power Equipment and Technology Co., Ltd. (CET), relating to the proposed hybrid renewable power plant for the group's green hydrogen and green ammonia project (Project) in Pakistan. The Project, which is being developed by the Company's joint venture company, Oracle Energy Limited (Oracle Energy), is targeting a 400 MW capacity green hydrogen production facility with annual production of 55,000 tonnes of green hydrogen. The completed power study confirms that the Project is expected to deploy 800MW of solar (an increase from the original 700 MW), 500MW of wind power, and 450MWh of battery energy storage to support the production of green hydrogen.

Physiomics* 1.6p £2.2m (PYC.L)
The mathematical modelling and data science Company supporting the development of new therapeutics and personalised medicine solutions announces an award of share options over ordinary shares of 0.4p each in the Company. The Company considers that it is important to incentivise its key executives to create shareholder value and, as such, the Board has approved the award of the following options to Dr Peter Sargent under the Company's existing share option scheme: 1) 1,354,725 Options with exercise price of 1.55p, 2) 1,354,725 Options with exercise price of 2.55p, being the exercise price calculated in (1) above plus 1p and 3) 1,354,725 Options with exercise price of 3.55p, being the exercise price calculated in (1) above plus 2p. All Options can be exercised within 10 years of the date of grant.

REACT Group 1.35p £14.4m (REAT.L)
The cleaning, hygiene, and decontamination company, announces its audited final results for the year ended 30 September 2023. Revenue increased by 43% to £19.6m (2022: £13.7m), as a result gross profit up 61% to £5.2m (2022: £3.3m). Adjusted EBITDA up 133% to £2.3m (2022: £1.0m), and the Company has cash as at 30 September 2023 of £2.1m. The Company announces it has completed its integration of LaddersFree during the year, and has good momentum into FY24 a strong first quarter.

Roquefort Therapeutics* 6.15p £7.9m (ROQ.L)
The biotech company focused on developing first in class medicines in the high value and high growth oncology market, provides an update on its pre-clinical drug development programs, Randox licencing agreement and out-licencing discussions. The Company has continued studies in validated models of NK cell activation and cytotoxicity and demonstrated an anti-cancer effect in leukaemia. The Randox licensing agreement is progressing well, and the Company expects to receive further milestone payments during 2024 and, upon success, this is expected to generate royalties for the Company from 2025. In line with its strategy, the Company is currently engaged in confidential out-licencing discussions with potential partners, including large pharmaceuticals companies and a specialist private equity fund.

Springfield Properties 82.5p £97.9m (SPR.L)
A housebuilder in Scotland focused on delivering private and affordable housing, announces that it has signed a new contract, worth £15.3m, with Highland Housing Alliance (HHA) for the delivery of affordable housing. The contract includes an initial bulk sale of housing, followed by a design and build aspect. The Group will receive £4.1m for a bulk sale of housing, which is scheduled to complete during the current financial year. The design and build phase, which is worth £11.2m, is due to commence in the coming weeks, with the majority of the revenue to be recognised in the Group's next financial year.

6 February 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram